NYSE: CNC · Healthcare Plans
Centene (CNC) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Centene (CNC) at $86.49 a share. The stock last closed at $74.77, which puts the model's fair value 15.7% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. Centene Corp.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $84.53 to $86.49 (+2.3%). The multiple the model anchors on moved, lifting the fair value: most of the move.
What the model makes of itThe price of $74.77 is 15.7% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 5 Feb 2027. Options prices imply a move of about 11% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give CNC?
The calibrated range for CNC over 63 trading days is $65.58 to $85.82. It sits around the last close, and its width comes from the volatility that CNC's own options imply (40% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $73.34 to $101.89. In 85% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other.
Faircurve's model put the fair value at $86.49 a share on 14 Nov 2026. The previous run, on 7 Nov 2026, gave $84.53, so the fair value moved +2.3%. The model gives the reason in its own words: the multiple it anchors on moved, lifting the fair value, and that is most of the move. The calibrated range over 63 trading days is $65.58 to $85.82, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It does not say whether the fair value is right.
Centene scores 50 out of 100 on the model's overall quality measure against comparable companies. Earnings quality is highest at 100, with FCF / net income at 2.71x against a peer median of 0.56x. Profitability is lowest at 6, with ROIC at 4.5% against a peer median of 10.6%. The model compares Centene with Humana Inc. (HUM), Cigna Corporation (CI), Elevance Health Inc. (ELV), Molina Healthcare, Inc. (MOH), CVS Health Corp. (CVS), UnitedHealth Group Incorporated (UNH) and Progyny, Inc. (PGNY).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does CNC report earnings, and how has the stock reacted?
Centene's next earnings report is scheduled for 5 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 5.6% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. CNC's 30 day implied volatility works out to about 11.5% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CNC's last 8 reports, ignoring direction, was 4.1%.
What the options market has priced for a month's move in CNC
How does CNC score on business quality?
Centene's overall quality score is 50 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 6 | 4.5%ROIC | 10.6% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | 2.71xFCF / net income | 0.56x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 65 | 19.4%Revenue growth, trailing | 11.7% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 49 | 0.2%Net buybacks / market value | 2.8% |
| Balance sheetNet debt to EBITDA and interest coverage. | 85 | -1.36xNet debt / EBITDA | 2.34x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 17 | 2.1 ptsEBITDA margin downside volatility, 5y | 0.8 pts |
How does CNC compare with similar companies?
The companies in healthcare plans closest to Centene in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| HUM Humana Inc. | $461.25 | $411.63 | -10.8% | Fairly valued |
| CI Cigna Corporation | $300.16 | $384.76 | +28.2% | Undervalued |
| ELV Elevance Health Inc. | $446.28 | $454.75 | +1.9% | Fairly valued |
| MOH Molina Healthcare, Inc. | $233.09 | $227.64 | -2.3% | Fairly valued |
| CVS CVS Health Corp. | $88.59 | $89.93 | +1.5% | Fairly valued |
| UNH UnitedHealth Group Incorporated | $412.02 | $405.70 | -1.5% | Fairly valued |
| PGNY Progyny, Inc. | $37.15 | $34.78 | -6.4% | Fairly valued |
What the comparable companies' multiples alone would give for CNC, the peer-implied price, is $133.98 a share on this run. The fair value weighs that against the company's own multiple.
Centene at a glance
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other.
- Market value
- $35.3B
- Sector
- Healthcare
- Industry
- Healthcare Plans
- Revenue expected, next twelve months
- $195.8B
- Consensus revenue growth, next fiscal year
- +2.8%
- Analysts with estimates
- 12
- Beta to the US market
- 0.37
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. CNC was among them.
How the fair value is worked out: the model prices Centene on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for CNC was $84.53. As of 14 Nov 2026 it is $86.49, a change of +2.3%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Centene's valuation
Is Centene stock undervalued or overvalued?
On Faircurve's model, CNC reads as Undervalued as of 14 Nov 2026. The model's fair value is $86.49 a share against a last close of $74.77, a gap of +15.7%.
What is CNC's fair value?
$86.49 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $73.34 to $101.89.
What price range does the model give CNC?
$65.58 to $85.82 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Centene report earnings next?
The next report is scheduled for 5 Feb 2027. Companies can move their dates.
How much has CNC moved on past earnings reports?
Across its last 8 reports the median two session move was 4.1%, ignoring direction. The largest was +24.1% around the report of 28 Apr 2026.
How confident is the model in this valuation?
The model's evidence grade for CNC is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on CNC
The model holds no idea open on CNC today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CNC with their outcomes. A free account is enough.